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BACKGROUND. Rituximab in sequential combination with fludarabine (Flu)
allowed patients with B-cell chronic lymphocytic leukemia (B-CLL) to achieve
higher remission rates and longer response duration. Based on their recent expe-
rience in indolent non-Hodgkin lymphomas, in this study, the authors attempted
to demonstrate whether consolidation/maintenance therapy with rituximab could
prolong the response duration in this patient population.
METHODS. This Phase II study was based on a consolidation/maintenance ther-
apy with rituximab for patients in complete remission (CR) or partial remission
(PR) who were positive for minimal residual disease (MRD), as determined by
flow cytometry. Seventy-five symptomatic, untreated patients with B-CLL
received 6 monthly cycles of Flu (25 mg/m2 for 5 days) followed by 4 weekly
doses of rituximab (375 mg/m2). Then, 28 patients who were positive for MRD
were consolidated with 4 monthly cycles of rituximab (375 mg/m2) followed by
12 monthly low doses of rituximab (150 mg/m2).
RESULTS. Based on National Cancer Institute criteria, 61 of 75 patients (81%)
achieved a CR, 10 of 75 patients (13%) had a PR, and 4 of 75 patients (5%) had
either no response or disease progression. MRD-positive patients in CR or PR
who received consolidation therapy (n 5 28 patients) had a significantly longer
response duration (87% vs 32% at 5 years; P 5 .001) compared with a subset of
patients who did not receive consolidation therapy (n 5 18 patients). All patients
experienced a long progression-free survival from the end of induction treatment
(73% at 5 years). It was noteworthy that, within the subset of ZAP-70-positive
patients, MRD-positive, consolidated patients (n 5 12 patients) had a signifi-
cantly longer response duration (69% vs 0% at 2.6 years; P 5 .007) compared with
MRD-positive, unconsolidated patients (n 5 11 patients).
CONCLUSIONS. The addition of a consolidation and maintenance therapy
with rituximab prolonged response duration significantly in patients with MRD-
positive B-CLL. Cancer 2008;112:119–28.  2007 American Cancer Society.
KEYWORDS: B-cell chronic lymphocytic leukemia, minimal residual disease, con-
solidation and maintenance therapy with rituximab, ZAP-70, CD38, immunoglobu-
lin heavy-chain variable-region status, cytogenetics, response duration.
C hronic lymphocytic leukemia (CLL) is the most common formof leukemia in the Western world, and it affects mainly elderly
individuals. Patients with CLL have variable outcomes, and survival
ranges from months to decades.1,2
Promising results were observed when fludarabine was intro-
duced for patients who were treated with alkylator agents and
for those with symptomatic, untreated CLL.3,4 However, despite
response rates as high as 70%, complete remissions (CR) were
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infrequent, and the longer progression-free survival
(PFS) in the fludarabine arm from 3 randomized stud-
ies5–7 did not produce significantly improved overall
survival (OS).
Rituximab is a chimeric monoclonal antibody
directed against the cell-surface antigen CD20, which
is active in low-grade and diffuse large-cell non-Hodg-
kin lymphoma (NHL).8,9 Moreover, experimental data
indicate a potential additive effect of combining ritux-
imab with fludarabine because of enhanced sensitivity
of tumor cells to chemotherapy-induced apoptosis.10
Three Phase II studies combining rituximab with flu-
darabine have achieved a much higher CR rate than
the rate reported previously with any other therapeu-
tic approach in CLL.11–13 Although to our knowledge
there is no proof to date of an improvement in OS,
disease-free progression has been prolonged. Signifi-
cantly, not only has the CR rate increased dramati-
cally, but it also has proved possible to eradicate
minimal residual disease (MRD) in an increasing pro-
portion of patients. In 224 patients with untreated
CLL who received combined fludarabine, cyclophos-
phamide, and rituximab, Keating et al.14 demonstrated
that flow cytometry-negative or minimally positive
bone marrow (BM) at the completion of therapy was
correlated with improved OS. Therefore, studies using
MRD assays by 4-color flow cytometry or molecular
methods may be better for confirming a true CR,
which should be the major therapeutic objective to
improve PFS and OS in patients with CLL. Recently,
the eradication of detectable MRD by 4-color flow
cytometry with the combination of alemtuzumab and
fludarabine was associated with improved OS and
treatment-free survival.15
In addition, it has been demonstrated that rituxi-
mab maintenance therapy provides a significant PFS
benefit in patients with indolent B-cell NHL.16,17
Therefore, the drug potentially may be useful as
maintenance therapy in patients with indolent NHL
or CLL.18–21
Recent literature data indicate that unmutated
VH genes, CD38 or ZAP-70 protein tyrosine kinase
overexpression, and positive MRD status may predict
either a lower response, a shorter PFS, or a shorter
OS.22–27 In the current study, our objective was to
demonstrate that a consolidation and maintenance
therapy with rituximab administered to symptomatic,
untreated patients in clinical CR or partial remission
(PR) but with detectable MRD, as determined by flow
cytometry, may prolong PFS. Finally, we evaluated
the different clinical impact of relevant biologic fea-
tures, such as ZAP-70, CD38, and immunoglobulin
heavy-chain variable-region (IgVH) status and cyto-
genetics, on response duration.
MATERIALS AND METHODS
From March 2000 to February 2005, 46 patients were
registered in this prospective Phase II study on con-
solidation/maintenance with rituximab. The study
was conducted in accordance to the Declaration of
Helsinki. The current analysis was performed in July
2006. All eligible patients provided written informed
consent and had received prior induction therapy for
CLL based on sequential combination of fludarabine
with rituximab, as described previously.13 Patients
were required to have histologically and immuno-
phenotypically documented CLL, as defined by the
modified National Cancer Institute (NCI) 1996 guide-
lines.28 An Eastern Cooperative Oncology Group
(ECOG) performance status from 0 to 2 was required.
Patients were excluded if they had active opportunis-
tic infections, any other severe infection that was
not controlled by medical therapy, or major organ
dysfunction.
Cellular Immunophenotypic Analysis
Peripheral blood mononuclear cells were analyzed
for surface expression of CD19/CD5/CD38 and
CD19/CD5/CD23 by triple-color immunofluores-
cence, as described previously.24 ZAP-70 protein
determination was performed by flow cytometry, as
described elsewhere.24,25 Flow cytometric analysis
was performed on a FACS Calibur flow cytometer
(Becton Dickinson Immunocytometry Systems, San
Jose, Calif), and CellQuest software was used to ac-
quire and analyze data. The threshold of positivity
both for CD38 and for ZAP-70 was set at >20%
CD19-positive (CD191)/CD51 B cells.
MRD Flow Cytometric Study
Between 50,000 and 300,000 total cells were analyzed
in each test performed in BM approximately 1 to 2
months after the completion of induction therapy.
The antibodies used were anti-CD5-allophycocyanin,
anti-CD20-phycoerythrin (PE), anti-CD19-peridin-
chlorophyll protein, anti-CD38-PE, anti-CD20-fluo-
rescein isothiocyanate (FITC) (Becton Dickinson),
and anti-CD79b-FITC (Serotec, Oxford, United King-
dom). The 2 combinations CD19/CD5/CD20/CD79b
and CD19/CD5/CD38/CD20 allowed us to discrimi-
nate B-CLL cells from normal B cells in all analyses,
as previously described.27 The threshold of positivity
was set at >1% CD191/CD51/CD79b-negative
(CD79b2) CLL cells.
Interphase Fluorescence In Situ Hybridization
Separate hybridizations were performed for loci on
chromosomes 11, 12, 13, and 17. For chromosomes
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11 (q23), 13, and 17, commercial probes (ATM-2, Rb-
1, and p53, respectively) were used (Vysis Inc.,
London, United Kingdom). An a satellite DNA probe
CEP12, which was labeled directly with Spectrum-
Green, was used to detect aneuploidy of chromo-
some 12. LSIp53 labeled with SpectrumOrange (Vysis
Inc.) was used to evaluate chromosome deletion at
17p13.1. The procedure used has been described pre-
viously.29
IgVH Mutation Analysis
Total RNA was extracted and reverse-transcribed as
reported previously.30 The resulting combinational
DNAs, which were checked for first-strand synthesis,
were amplified by using a mixture of sense primers
annealing either to the VH1 through VH6 leader
sequences or to the 50 end of VH1 through VH6 FR1,
as reported.31,32 VH gene sequences that deviated
>2% from the corresponding germline gene were
defined as mutated. The procedure that we used was
described previously.13
Treatment Plan
For induction treatment, all patients received daily
fludarabine (25 mg/m2) delivered intravenously on
days 1 through 5 of 28-day intervals for a total of 6
cycles. Then, patients with stable disease or better,
as defined by the NCI criteria, received 4 weekly
doses of rituximab (375 mg/m2), as reported pre-
viously.13 Patients were observed for approximately 1
month and then were restaged completely to deter-
mine their overall response according to the NCI
1996 criteria.28 At this point, we performed a careful
immunophenotypic BM evaluation in which samples
with CD191/CD51/CD79b2 cells >1% were consid-
ered positive for MRD. Furthermore, we continued
monitoring the immunophenotype of the peripheral
blood lymphocytes (PBLs) every month for 1 year in
MRD BM-negative patients; and, when CD191/
CD51/CD79b2 (MRD) PBLs were >1000/mL, a new
BM immunophenotypic analysis was performed.
Based on this threshold in peripheral blood, all of
these patients also had MRD-positive BM (>1%).
Therefore, both of these patient subsets (n 5 28
patients), 1 subset (n 5 17 patients) in clinical CR or
PR who were MRD-positive after induction and
another subset (n 5 11 patients) in CR who were
MRD-negative after induction but who became
MRD-positive within 1 year, underwent consolida-
tion/maintenance therapy with 4 monthly cycles of
rituximab at 375 mg/m2 followed by 12 monthly
doses of rituximab at 150 mg/m2 (Fig. 1A,B). In
FIGURE 1. (A) Flow chart of patient groups. Chronic lymphocytic leukemia populations (induction, consolidation/maintenance, observation, minimal residual
disease [MRD] status) are detailed; CR indicates complete remission; PR, partial remission; pts, patients; BM, bone marrow; 1, positive; PB, peripheral blood;
2, negative. (B) Rituximab consolidation and maintenance scheme. Twenty-eight MRD-positive patients in clinical CR or PR underwent consolidation/mainte-
nance therapy with 4 monthly cycles of rituximab at a dose of 375 mg/m2 followed by 12 monthly doses of rituximab at a dose of 150 mg/m2.
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detail, inclusion in the consolidation/maintenance
treatment group for each patient was determined
either immediately after induction in BM MRD-
positive patients or soon after the detection of MRD
in BM in BM MRD-negative patients within 1 year.
Eighteen patients with clinical and biologic character-
istics similar to those of the consolidation/mainte-
nance group underwent observation only. The
complete outline of the study is provided in Figure 1A.
Assessment and Management of Toxicity During
Consolidation/Maintenance Treatment
Hematologic toxicity was graded according to the
modified NCI criteria for CLL,28 whereas nonhemato-
logic toxicity was graded according to the NCI Com-
mon Toxicity Criteria. Infusion toxicity was assessed
according to the criteria described previously by
Byrd et al.12 Patients who experienced grade 3 or
4 neutropenia were supported with growth factors
(granulocyte–colony-stimulating factor) and re-
mained without treatment until this parameter
recovered within 50% of the baseline value. There-
after, they received the same original dose. There
were no dose reductions for rituximab therapy
because of hematologic toxicity. At the onset of fever,
chills, rigors, or other infusional reactions, patients
had their infusion discontinued; and, after the reso-
lution of symptoms, the rituximab infusion was
restarted at a rate of 50 mg per hour and then esca-
lated as tolerated to 200 mg per hour. Patients who
developed an infection were observed without fur-
ther CLL treatment until the infection had resolved,
but no dose reductions were implemented.
Patient Monitoring and Response Evaluation
Patients were assessed for induction response 4
weeks after the last rituximab infusion with a
detailed clinical and instrumental evaluation, as
reported previously.13 These same evaluations were
performed at the end of consolidation/maintenance
therapy. Criteria for response used the revised 1996
NCI Working Group guidelines.28 A CR or PR had to
be maintained for at least 8 weeks. PFS was defined
as the time from the end of induction treatment in
the subgroup of patients who achieved a CR or PR,
encompassing the time of consolidation/mainte-
nance treatment, until the last follow-up, the time at
which disease progression occurred, or the time of
death from any cause. Similarly, OS was measured
from the end of induction treatment to either the
last time the patient was seen alive or the date of
death.
Sample Size Determination
With a 2-sided significance level (a) of 5% and an
80% power 1-b, in total, 46 patients would be eligible
to receive consolidation and maintenance therapy,
and 12 events would be enough to reveal a 55%
increase in 5-year PFS after inclusion in the study
(from 32% to 87% in the consolidation/maintenance
group).33
Statistical Analysis
For the efficacy analysis, patients had to have
received at least 1 cycle of therapy. Rate comparisons
between patient subgroups were performed by using
the 2-tailed Fisher exact test. Event-related data (sur-
vival and PFS) were estimated by using the Kaplan-
Meier product limit method. Prognostic subgroups
were compared by using the log-rank test. Statistical
analysis and Kaplan-Meier curves were performed
using Statistica software (version 6.0 for Windows).
RESULTS
Patient Characteristics
The pretreatment features of the patients are sum-
marized in Table 1. The median age was 60 years
(range, 37–74 years). All patients met the guidelines
criteria for having CLL.27 According to Rai staging
criteria,1 7 patients (9%) had low-risk CLL (stage 0),
65 patients (87%) had intermediate-risk CLL (stage I
or II), and 3 patients (4%) had high-risk CLL (stage
III or IV). More than half of the patients (55%) had a
good ECOG performance status (0). The time from
diagnosis to treatment ranged from 1 to 10 years.
Only 23 of 75 patients (31%) exhibited B symptoms.
TABLE 1
Patient Characteristics (n 5 75)
Characteristic No. of patients (%)






B symptoms 23 (31)
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Toxicity
Focusing on the consolidation and maintenance pro-
gram, the 3 most frequent side effects were infusion-
related toxicity, myelosuppression, and infections.
Four of 28 patients who received rituximab in conso-
lidation/maintenance experienced a mild infusion-
related symptom complex consisting of fever, chills,
and rigors. There were 7 opportunistic infections,
including 3 dermatomal herpes zoster infections and
4 localized herpes simplex infections, but no pulmo-
nary toxicity was observed. Hematologic toxicity
included only neutropenia (grade 1 and/or 2 in 8
patients, grade 3 and/or 4 in 4 patients) during ritux-
imab treatment.
Response to Treatment and Treatment Outcome
All patients who were enrolled on this study (n 5 75
patients) were evaluable for response. The response
induction rate included a first induction CR rate of
65% after fludarabine that jumped to 83% after ritux-
imab. Seventy-one patients in CR or PR after induc-
tion entered the protocol consolidation and
maintenance study (Table 2). MRD analysis per-
formed on BM by flow cytometry after induction
therapy was positive (>1% CD191/CD51/CD79b2
CLL cells) in 29 of 71 patients (41%). All patients in
PR (n 5 10) were positive for MRD, and 19 of 61
patients in CR (31%) were positive for MRD (Fig. 1A).
Twenty-eight patients (22 in CR and 6 in PR) who
either had CD51/CD191/CD79b2 MRD BM cells
>1% (n 5 17 patients) immediately after induction
treatment or initially were MRD BM-negative but who
presented with MRD in PBLs >1000/mL (n 5 11
patients) within 1 year after the completion of induc-
tion treatment underwent consolidation/maintenance
therapy with rituximab. Eighteen patients (14 in CR
and 4 in PR) who presented with similar biologic and
clinical features underwent observation only, including
12 patients with MRD-positive BM after induction and
6 patients with MRD in PBLs >1000/mL within 1 year
(Table 3). In addition, 25 patients in CR with persis-
tently MRD-negative BM (>1 year) were observed only
and compared with the subset of consolidated patients
in terms of PFS.
Outcome data relative to PFS and OS are shown
in Figures 2A and 2B. The estimated 5-year PFS after
the end of induction treatment was 73% (Fig. 2A).
After a median of 26 months of follow-up from
the beginning of consolidation/maintenance or obser-
vation (March 2000), until the end of June 2006, 13 of
71 patients (18%) experienced disease recurrence.
Among the 46 patients who were enrolled in the
consolidation/maintenance or observation study, 3
patients died. One patient died in CR of a fulminant B
hepatitis, and 2 other patients died of progressive CLL
after receipt of the prescribed protocol therapy.
It is interesting to note that MRD-positive
patients who underwent consolidation therapy
(n 5 28 patients) had a significantly longer response
duration (87% vs 32% at 5 years; P 5 .001) (Fig. 3A)
compared with the subset of patients who were not
consolidated and were positive for MRD in BM or
PBLs (n 5 18 patients). It also is worth noting that
patients with persistently MRD-negative BM (>1
year; n 5 25 patients) had a response duration simi-
lar to that of the consolidated patients (Fig. 3B).
Clinical and Biologic Features Predicting Response
and Outcome
Thirty-five patients (47%) were identified who had
ZAP-70 expression >20% (range, 4–70%), and 23 of




No. of patients (%)
Total no. CR PR SD or PD
Fludarabine induction 75 49 (65) 21 (28) 5 (7)*
Rituximab induction 73 61 (83) 10 (14) 2 (3)
CR indicates complete response; PR, partial response; SD, stable disease; PD, progressive disease.
* Three patients presented with SD and therefore underwent rituximab induction; 71 patients in CR
or PR after induction with fludarabine plus rituximab entered the consolidation and maintenance
protocol.
TABLE 3












Date first patient enrolled July 2000 March 2000
Date last patient enrolled January 2005 February 2005
Median time (MRD-BM1), mo* 1 1
Median time (MRD-PB1), mo* 3.6 3.5
Median follow up (range)y 31.5 (11–72) 20.5 (3–62)
MRD indicates minimal residual disease; BM, bone marrow; 1, positive, PB, peripheral blood.
* Between the end of induction and the beginning of consolidation or observation.
y From the beginning of consolidation/maintenance or observation.
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(range, 1–69%). Fifty-three patients were analyzed by
interphase fluorescence in situ hybridization: In that
analysis, 26 patients (49%) had a normal karyotype,
15 patients (28%) had deletion (del) 13q abnormality,
and 12 patients (23%) had an ‘‘intermediate/high-
risk’’ karyotype encompassing trisomy 12 (5
patients), del 11q (5 patients), and del 17p (2
patients). Forty-seven patients were analyzed for
IgVH mutations: In that analysis, 19 of 27 patients
with IgVH mutations <2% presented with ZAP-70
protein >20% (P 5 .0002). Moreover, the strict rela-
tion between CD38 and IgVH mutational status was
confirmed (15 of 17 patients with IgVH mutations
<2% had CD38 values >20%; P 5 .00002).
A significantly shorter PFS from the end of
induction was observed among ZAP-701 patients
(40% vs 96% at 5 years; P 5 .00002) (Fig. 4A), CD381
patients (30% vs 88% at 5 years; P 5 .001) (Fig. 4B),
unmutated patients (0% vs 92% at 2.1 years;
P 5 .0003) (Fig. 4C), and within the ‘‘intermediate/
high-risk’’ (trisomy 12, or del 11q, or del 17p) cytoge-
netic subset (0% vs 88% at 2.1 years; P 5 .02) (Fig.
4D). It is noteworthy that, within the ZAP-701 subset
(n 5 35 patients), considering only the MRD-positive
patients who were in CR or PR (n 5 23 patients),
patients in the consolidated group (n 5 12) had a
significantly longer response duration (69% vs 0% at
2.6 years; P 5 .007) (Fig. 5) compared with patients
in the observation-only group (n 5 11).
DISCUSSION
In this Phase II study, we confirmed that induction
immunochemotherapy consisting of 6 cycles of flu-
FIGURE 2. (A) Kaplan-Meier analysis of progression-free survival (PFS). The
proportion of 71 patients who responded to treatment and remained in com-
plete or partial remission are shown. The estimated 5-year PFS rate from the
end of induction was 73%. Thirteen of 71 patients (18%) experienced disease
recurrence. O, observed events. (B) Kaplan-Meier analysis of overall survival
from the end of induction for 71 patients with chronic lymphocytic leukemia. At
the time of last follow-up, 3 patients had died either of progressive disease or
of opportunistic infections. O indicates observed events.
FIGURE 3. (A) Response duration by consolidation (Cons) and maintenance
(Mant) in patients (pts) who were positive for minimal residual disease
(MRD). Twenty-eight MRD-positive consolidated (Cons) patients had a longer
response duration compared with 18 MRD-positive nonconsolidated patients
(P 5 .001). Obs indicates observed patients; O, observed events. (B)
Response duration in consolidated MRD-positive patients versus observed
persistently MRD-negative (neg) patients. Twenty-five MRD-negative uncon-
solidated patients demonstrated a similar response duration compared with
28 MRD-positive consolidated patients.
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darabine followed by 4 cycles of rituximab was very
effective in patients with untreated B-CLL, and we
demonstrated that consolidation/maintenance ther-
apy with rituximab prolonged the response duration
in MRD-positive patients. Rituximab dramatically
increased response rates. After fludarabine therapy,
65% of patients achieved CR. This CR rate jumped to
83% after rituximab treatment. This very high CR
rate was achieved because nearly all of our patients
(65 of 75 patients) had intermediate Rai stage dis-
ease. In fact, the treatment of this progressive subset
before the appearance of anemia or thrombocytope-
nia allowed us to obtain very good results in terms of
both response and response duration. It is note-
worthy that PFS outcomes also were impressive after
rituximab, and the consolidation/maintenance
approach using the same drug resulted in an
improved 5-year PFS rate of 73%. Moreover, this
treatment regimen is feasible and can be adminis-
tered safely on an outpatient basis. The risk of
opportunistic infections may increase at first by
combining fludarabine and rituximab in induction
and then prolonging rituximab infusions in the con-
solidation and maintenance therapy, because fludar-
abine leads to profound depletion of T cells, whereas
rituximab causes prolonged depletion of B lympho-
cytes.34,35 During consolidation/maintenance, most
of these infections were viral, and they often were
localized. Grade 3 and/or 4 hematologic toxicity was
observed almost exclusively for neutropenia. None-
FIGURE 4. These progression-free survival (PFS) curves were based on ZAP-70 (A), CD38 (B), immunoglobulin heavy-chain variable-region (IgVH) mutational
status (C), and cytogenetics by fluorescence in situ hybridization (D). PFS from the end of induction (indicated in months) was significantly shorter in patients
who had ZAP-70 levels >20% (ZAP-70-positive [ZAP-701] vs ZAP-70-negative [neg]), CD38 levels >20% (CD381 vs CD38-negative [CD382]), IgVH unmu-
tated status (UM) (vs mutated [M]), and ‘‘intermediate/high-risk’’ cytogenetic status (trisomy 12, deletion 11q, deletion 17p).
FIGURE 5. Duration of response within the ZAP-70-positive (1) patient
subset. Minimal residual disease (MRD)-positive consolidated (Cons) patients
had a significantly longer response duration compared with MRD-positive
unconsolidated patients. Obs, observed patients; O, observed events.
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theless, this excess neutropenia did not predispose
patients to an excess number of neutropenic fever
episodes or life-threatening infections.
Moreover, there was no event of autoimmune
hemolytic anemia, most likely because the transient
B-cell depletion caused by rituximab may avoid the
development of fludarabine-associated hemolytic
anemia. One concern regarding the use of rituximab
in patients with CLL, particularly in consolidation/
maintenance, may be infusion-related toxicity. Stu-
dies have demonstrated that rituximab can cause
severe infusion-related toxicity in a minority of
patients and that a high number of circulating B-CLL
cells may predispose patients to this problem.36 In
our study, only 4 patients had a mild infusion-related
symptom complex, which consisted of fever, chills,
and rigors, during consolidation/maintenance with
rituximab. Most likely, the low infusion toxicity
observed with rituximab treatment during consolida-
tion/maintenance was because of the lower leuko-
cyte counts.
The employment of an MRD assay by flow cyto-
metry allowed us to define patients in CR as positive
or negative for MRD. That is important, because
patients in CR based on NCI criteria who are positive
for MRD may develop recurrent disease more easily.
To avoid this risk, consolidation/maintenance ther-
apy with rituximab was proposed by our group.
Twenty-eight MRD-positive patients who were in CR
or PR before the consolidated treatment scheme had
a significantly increased 5-year PFS rate compared
with unconsolidated MRD-positive patients (Fig. 3A).
Therefore, rituximab consolidation/maintenance
therapy was crucial to prolonging PFS in MRD-posi-
tive patients, allowing them to reach the same
response duration as that achieved by persistently
MRD-negative patients (Fig. 3B). In data from the lit-
erature on patients with follicular lymphoma, a >2-
fold longer duration of remission was achieved with
rituximab maintenance compared with observation
in a multicenter, Phase III trial.16 Moreover, a histolo-
gic subgroup analysis from a randomized Phase II
trial of rituximab revealed longer PFS with the main-
tenance regimen than with the retreatment regimen
in patients with either follicular NHL (median, 31
months vs 13 months; n 5 62 patients) or B-cell CLL
(median, 34 months vs 6 months; n 5 28 patients).17
Moreover, the use of lower doses of rituximab during
the maintenance phase could reduce the loss of
CD20 antigen from the surface of circulating B
cells.37 It is believed that this process of antigenic
modulation occurs through ‘‘shaving off’’ of the
rituximab-CD20 complexes by monocytes or macro-
phages in a reaction mediated by Fcg receptors.37 In
fact, results from a pilot study in this patient popula-
tion suggest that the loss of CD20 antigen can be
reduced and the efficacy of rituximab can be
improved with the use of low doses of rituximab that
still provide adequate targeting and clearance of cir-
culating CD201 B lymphocytes.38 The efficacy of our
maintenance approach may be explained on the ba-
sis of this recent experience.38
Various clinical features, including age, Rai stage,
and serum b2-microglobulin, have been associated
with lower response and poor long-term treatment
outcomes after alkylator-based and purine analog-
based therapy for CLL.39 Recent studies examining
molecular aberrations (ie, p53 mutations), unfavor-
able cytogenetics, CD38 expression, somatic VH gene
mutational status, and ZAP-70 expression have
demonstrated that all of these factors are important
determinants for treatment outcome in patients with
CLL.40 It is interesting to note that, in our study,
higher ZAP-70 levels, CD38 overexpression, and IgVH
unmutated status identified subsets of patients who
had a poor prognosis with regard to PFS measured
from the end of induction treatment (Fig. 4). Thus,
these markers may be used prospectively to identify
subsets of patients who have a low likelihood of
improved outcomes with a rituximab consolidation
and maintenance approach. Conversely, an MRD
assay performed by flow cytometry may allow us
to identify MRD-positive patients who should be
treated with a consolidation/maintenance immu-
notherapy approach, because they are at the greatest
risk of disease recurrence. Furthermore, within the
ZAP-701 patients, considering only MRD-positive
patients, consolidated patients had a better course
than unconsolidated patients. Therefore, consolida-
tion and maintenance therapy with rituximab signifi-
cantly improves the clinical outcome of patients with
B-CLL.41 Our experience should encourage the use of
consolidation/maintenance treatment with rituximab
in CLL. In fact, the ultimate objective in CLL therapy
is not only to achieve high CR rates but also (and
mainly) to avoid disease recurrence, thus prolonging
remission duration and, finally, OS. Improved OS
may be expected in patients who receive rituximab
maintenance therapy because of the effect it has on
B-cell depletion; at 1-year follow-up, the level of cir-
culating B lymphocytes remained low in patients
who received rituximab maintenance, whereas it rose
above the baseline value in patients who received no
further rituximab treatment.16 In conclusion, our
study demonstrated that a consolidation and mainte-
nance therapy with rituximab further prolongs the
response duration in MRD-positive patients with B-
CLL.
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